REG - EKF Diagnostics Hldg - Total Voting Rights

EKF Diagnostics HoldingsAnnouncement

02/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB8531Ka&default-theme=true

RNS Number : 8531K  EKF Diagnostics Holdings PLC  02 June 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Total Voting Rights

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, in accordance with the Financial Conduct Authority's Disclosure and
Transparency Rules, announces that the total issued share capital of the
Company consists of 454,930,564 Ordinary Shares of one penny each, of which
5,836,774 Ordinary Shares are held in treasury. Therefore, the total number of
Ordinary Shares carrying voting rights will be 449,093,790.

 

The above figure of 449,093,790 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR

 Gavin Jones, Chief Executive Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Oliver Platts

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREADSEDLNSEFA